Improved 32P-postlabelling assay for the quantification of the major platinum-DNA adducts.

No abstract is available for this paper.

• Publication year

  1997

• Venue

  Carcinogenesis

• Publication date

  1997-09-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1093/CARCIN/18.9.1767PMID 9328174
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Antibodies against cisplatin-modified DNA and cisplatin-modified (di) nucleotides

  2004cited by this paper
• Detection of Adducts Formed upon Treatment of DNA with Cisplatin and Carboplatin

  1996cited by this paper
• Effects of thiourea and ammonium bicarbonate on the formation and stability of bifunctional cisplatin-DNA adducts: consequences for the accurate quantification of adducts in (cellular) DNA.

  1995cited by this paper
• Detection of platinum-DNA adducts by 32P-postlabelling.

  1995cited by this paper
• Comparison of TLC- and HPLC-32P-postlabelling assay for cisplatin-DNA adducts.

  1994cited by this paper
• A 32P-postlabelling assay for DNA adducts induced by cis-diamminedichloroplatinum(II).

  1994cited by this paper
• The growth inhibiting effect of docetaxel (Taxotere) in head and neck squamous cell carcinoma xenografts.

  1994cited by this paper
• Pharmacokinetic-dynamic relationship of cisplatin in vitro: simulation of an i.v. bolus and 3 h and 20 h infusion.

  1994cited by this paper
• Drug-induced DNA modification in buccal cells of cancer patients receiving carboplatin and cisplatin combination chemotherapy, as determined by an immunocytochemical method: interindividual variation and correlation with disease response.

  1993cited by this paper
• Fluorescent postlabelling of modified DNA bases.

  1993cited by this paper
• Fluorescence postlabeling assay of DNA damage induced by N-methyl-N-nitrosourea.

  1993cited by this paper
• A novel technique to assay adducts of DNA induced by anticancer agent cis-diamminedichloroplatinum(II).

  1991cited by this paper
• Sensitive detection of DNA modifications induced by cisplatin and carboplatin in vitro and in vivo using a monoclonal antibody.

  1991cited by this paper
• A simple salting out procedure for extracting DNA from human nucleated cells.

  1988cited by this paper
• Synthesis and application of fluorescent labeled nucleotides to assay DNA damage.

  1988cited by this paper
• cis-Diamminedichloroplatinum(II)-induced DNA adducts in peripheral leukocytes from seven cancer patients: quantitative immunochemical detection of the adduct induction and removal after a single dose of cis-diamminedichloroplatinum(II).

  1987cited by this paper
• Quantitation of cis-diamminedichloroplatinum II (cisplatin)-DNA-intrastrand adducts in testicular and ovarian cancer patients receiving cisplatin chemotherapy.

  1986cited by this paper
• Reevaluation of interaction of cis-dichloro(ethylenediamine)platinum(II) with DNA.

  1986cited by this paper
• Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: formation, identification, and quantitation.

  1985cited by this paper
• Immunochemical quantitation of adducts induced in DNA by cis-diamminedichloroplatinum (II) and analysis of adduct-related DNA-unwinding.

  1985cited by this paper
• Characterization of a human ovarian adenocarcinoma line, IGROV1, in tissue culture and in nude mice.

  1985cited by this paper
• A simple method for the inactivation of monofunctionally DNA-bound cis-diamminedichloroplatinum (II).

  1984cited by this paper
• Detection and quantification of adducts formed upon interaction of diamminedichloroplatinum (II) with DNA, by anion-exchange chromatography after enzymatic degradation.

  1982cited by this paper
• Antibodies elicited against cis-diamminedichloroplatinum(II)-modified DNA are specific for cis-diamminedichloroplatinum(II)-DNA adducts formed in vivo and in vitro.

  1982cited by this paper
• Fluorescent modification of guanine. Reaction with substituted malondialdehydes.

  1976cited by this paper
• FLUORESCENT MODIFICATION OF GUANINE. REACTION WITH SUBSTITUTED MALONDIALDEHYDES

  1976cited by this paper

• Analytical approaches to investigating metal-containing drugs.

  2015cites this paper
• On the origins and development of the (32)P-postlabelling assay for carcinogen-DNA adducts.

  2013cites this paper
• Personalized medicine for targeted and platinum-based chemotherapy of lung and bladder cancer.

  2013cites this paper
• Therapy-induced carboplatin-DNA adduct levels in human ovarian tumours in relation to assessment of adduct measurement in mouse tissues.

  2012cites this paper
• Speciation of oxaliplatin adducts with DNA nucleotides.

  2011cites this paper
• A microdosing approach for characterizing formation and repair of carboplatin–DNA monoadducts and chemoresistance

  2011cites this paper
• Investigation of DNA adducts formed in cells and clinical tumour biopsies following exposure to platinum-containing anticancer drugs

  2011cites this paper
• Determination of Pt–DNA adducts and the sub-cellular distribution of Pt in human cancer cell lines and the leukocytes of cancer patients, following mono- or combination treatments, by inductively-coupled plasma mass spectrometry

  2011cites this paper
• Quantitative methods for studying DNA interactions with chemotherapeutic cisplatin

  2010cites this paper
• Determination of cisplatin 1,2-intrastrand guanine-guanine DNA adducts in human leukocytes by high-performance liquid chromatography coupled to inductively coupled plasma mass spectrometry.

  2010cites this paper
• Analytical methodologies for metallomics studies of antitumor Pt-containing drugs.

  2010cites this paper
• p53-dependent global nucleotide excision repair of cisplatin-induced intrastrand cross links in human cells.

  2008cites this paper
• The 32P-postlabeling assay for DNA adducts

  2007cites this paper
• Development of a liquid chromatography-electrospray ionization tandem mass spectrometry method for detecting oxaliplatin-DNA intrastrand cross-links in biological samples.

  2007cites this paper
• Effects of gemcitabine on cis-platinum-DNA adduct formation and repair in a panel of gemcitabine and cisplatin-sensitive or -resistant human ovarian cancer cell lines.

  2006cites this paper
• Analysis of DNA damage and cellular responses to platinum-based chemotherapeutic agents in 'in vitro' models of non-small cell lung cancer

  2005cites this paper
• GA and AG sequences of DNA react with cisplatin at comparable rates.

  2003cites this paper
• DETERMINATION OF PLATINUM IN CLINICAL SAMPLES

  2002cites this paper
• Separation and identification of platinum adducts with DNA nucleotides by capillary zone electrophoresis and capillary zone electrophoresis coupled to mass spectrometry

  2001cites this paper
• Schedule-dependent pharmacodynamic effects of gemcitabine and cisplatin in mice bearing Lewis lung murine non-small cell lung tumours.

  2000cites this paper
• The potential of plantinum-DNA adduct determination in ex vivo treated tumor fragments for the prediction of sensitivity to cisplatin chemotherapy.

  1999cites this paper
• 32P-postlabeling assay for the quantification of the major platinum-DNA adducts.

  1999cites this paper
• Pharmacokinetic schedule finding study of the combination of gemcitabine and cisplatin in patients with solid tumors.

  1999cites this paper
• Pharmacodynamics of cisplatin in human head and neck cancer: correlation between platinum content, DNA adduct levels and drug sensitivity in vitro and in vivo

  1999cites this paper
• Development and Application of a Simple Assay to Quantify Cellular Adducts of Platinum Complexes with DNA

  1999cites this paper